Company information
Aiming for a world where life-saving treatments are accessible and people's health is greatly improved.
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.

Business Activities
1. Import and export, manufacturing, development, sales, rental, and maintenance of the following products: - Reagents, consumables, equipment, and their accessories for biopharmaceutical manufacturing - Chemical substances and reagents for life science research, as well as physical and chemical measurement instruments 2. Research, studies, and contracting related to the products mentioned above, sales of databases and software, and licensing of implementation rights 3. Various training, consulting services, and analytical services related to the products and businesses listed above 4. Secondhand dealer based on the Secondhand Goods Dealer Act 5. All businesses related or ancillary to the above
Company overview
- Company name Cytiva
- Establishment October 1, 2019
- Address 〒169-0073 Tokyo/ Shinjuku-ku/ 3-25-1 Hyakunincho, Sunken Building View on map
- TEL 03-5331-9336
